medication use
Recently Published Documents


TOTAL DOCUMENTS

4806
(FIVE YEARS 1444)

H-INDEX

99
(FIVE YEARS 11)

2022 ◽  
Vol 10 (1) ◽  
pp. 100457
Author(s):  
Roel Van Overmeire ◽  
Lara Vesentini ◽  
Stephanie Vanclooster ◽  
Emilie Muysewinkel ◽  
Johan Bilsen

2022 ◽  
Vol 8 ◽  
Author(s):  
Alun D. Hughes ◽  
Sophie V. Eastwood ◽  
Therese Tillin ◽  
Nish Chaturvedi

Objectives:We characterised differences in BP control and use of antihypertensive medications in European (EA), South Asian (SA) and African-Caribbean (AC) people with hypertension and investigated the potential role of type 2 diabetes (T2DM), reduced arterial compliance (Ca), and antihypertensive medication use in any differences.Methods:Analysis was restricted to individuals with hypertension [age range 59–85 years; N = 852 (EA = 328, SA = 356, and AC =168)]. Questionnaires, anthropometry, BP measurements, echocardiography, and fasting blood assays were performed. BP control was classified according to UK guidelines operating at the time of the study. Data were analysed using generalised structural equation models, multivariable regression and treatment effect models.Results:SA and AC people were more likely to receive treatment for high BP and received a greater average number of antihypertensive agents, but despite this a smaller proportion of SA and AC achieved control of BP to target [age and sex adjusted odds ratio (95% confidence interval) = 0.52 (0.38, 0.72) and 0.64 (0.43, 0.96), respectively]. Differences in BP control were partially attenuated by controlling for the higher prevalence of T2DM and reduced Ca in SA and AC. There was little difference in choice of antihypertensive agent by ethnicity and no evidence that differences in efficacy of antihypertensive regimens contributed to ethnic differences in BP control.Conclusions:T2DM and more adverse arterial stiffness are important factors in the poorer BP control in SA and AC people. More effort is required to achieve better control of BP, particularly in UK ethnic minorities.


2022 ◽  
Vol 22 (1) ◽  
Author(s):  
M. J. H. Voshaar ◽  
B. J. F. van den Bemt ◽  
M. A. F. J. van de Laar ◽  
A. M. van Dulmen ◽  
J. E. Vriezekolk

Abstract Background Disease-modifying anti-rheumatic drugs (DMARDs) are the cornerstone of rheumatoid arthritis (RA) treatment. However, the full benefits of DMARDs are often not realized because many patients are sub-optimally adherent to their medication. In order to optimize adherence, it is essential that healthcare professionals (HCPs) understand patients’ barriers and facilitators for medication use. Insight in these barriers and facilitators may foster the dialogue about adequate medication use between HCPs and patients. What HCPs perceive as barriers and facilitators has, so far, scarcely been investigated. This study aimed to identify the perceptions of HCPs on patients’ barriers and facilitators that might influence their adherence. Methods This qualitative study was performed using semi structured in-depth interviews with HCPs. An interview guide was used, based on an adjusted version of the Theoretical Domains Framework (TDF). Thematic analysis was conducted to identify factors that influence barriers and facilitators to DMARD use according to HCPs. Results Fifteen HCPs (5 rheumatologists, 5 nurses and 5 pharmacists) were interviewed. They mentioned a variety of factors that, according to their perceptions, influence DMARD adherence in patients with RA. Besides therapy-related factors, such as (onset of) medication effectiveness and side-effects, most variation was found within patient-related factors and reflected patients’ beliefs, ways of coping, and (self-management) skills toward medication and their condition. In addition, factors related to the condition (e.g., level of disease activity), healthcare team and system (e.g., trust in HCP), and social and economic context (e.g. support, work shifts) were reported. Conclusions This study provided insights in HCPs’ perceptions of the barriers and facilitators to DMARD use patients with RA. Most factors that were mentioned were patient-related and potentially modifiable. When physicians understand patients’ perceptions on medication use, adherence to DMARDs can probably be optimized in patients with RA leading to more effectiveness of treatment outcomes.


JAMA Surgery ◽  
2022 ◽  
Author(s):  
Ryan Howard ◽  
Grace F. Chao ◽  
Jie Yang ◽  
Jyothi R. Thumma ◽  
David E. Arterburn ◽  
...  

2022 ◽  
pp. 136346152110686
Author(s):  
Steven Pirutinsky ◽  
David H. Rosmarin

Historical clinical reports and media narratives suggest that Orthodox Jews are reticent to seek treatment for mental illness, present only with serious concerns, and hesitate to comply with treatment in general and psychopharmacology in particular. On the other hand, recent developments, and some limited research, suggest that Orthodox Jews may be likely to seek and comply with treatment. The current study compared the diagnostic, symptomatic, and treatment characteristics of 191 Orthodox Jews and 154 control patients all presenting to a large private mental health clinic with offices throughout greater New York. Results indicated that the groups were largely demographically similar, and that their diagnoses did not significantly differ. Orthodox Jews initially presented with lower levels of symptoms, terminated with similar symptom levels, attended a similar number of sessions, and were equally likely to use psychopharmacological interventions of similar types, compared to controls. This was equally true of ultra-Orthodox and modern Orthodox Jews. Clinicians providing mental health services to Orthodox Jews should be aware of these findings, which contrast with existing clinical and popular stereotypes. Further, excessive efforts to protect Orthodox Jewish patients against stigma may be unnecessary and counterproductive.


2022 ◽  
pp. 20-25
Author(s):  
Amaris Fuentes ◽  
Mabel Truong ◽  
Vidya Salfivar ◽  
Mobolaji Adeola

Medication safety events with the potential for patient harm do occur in health care settings. Pharmacists are regularly tasked with utilizing their medication knowledge to optimize the medication use process and reduce the likelihood of error. To prepare for these responsibilities in professional practice, it is important to introduce patient safety principles during educational experiences. The Accreditation Council for Pharmacy Education (ACPE) and the American Society of Health-System Pharmacists (ASHP) have set forth accreditation standards focused on the management of medication use processes to ensure these competencies during pharmacy didactic learning and postgraduate training. The experience described here provides perspective on educational and experiential opportunities across the continuum of pharmacy education, with a focus on a relationship between a college of pharmacy and healthcare system. Various activities, including discussions, medication event reviews, audits, and continuous quality improvement efforts, have provided the experiences to achieve standards for these pharmacy learners. These activities support a culture of safety from early training.


2022 ◽  
pp. 30-35
Author(s):  
Rowan Elkeshawi ◽  
Katherine Maddox ◽  
Andriana Xenophontos ◽  
Kyle Hampson

The delivery of safe and effective healthcare to pediatric and neonatal patients presents unique challenges to the medication-use system. The diversity of patients within this population and the consequences of ontogeny on pharmacokinetics and pharmacodynamics directly impact the safe use of medications in children and increase the risk of adverse drug events.1 This review will explore the medication-use system for hospitalized children and neonates, discuss vulnerabilities within this system, and provide examples of advancements made to improve the pediatric medication-use system.


2022 ◽  
Vol 11 (1) ◽  
pp. e44011125251
Author(s):  
Gilberto Gomes Soares Júnior ◽  
Omar Ayub ◽  
Jose Carlos Gasparim ◽  
Luciana Maria Malosá Sampaio ◽  
José Celso Contador ◽  
...  

During a flight, changes occur in the human body, whose possible reactions can influence the well-being and quality of health of medicine users, subject of scarce studies. The aim of this paper is to analyze the impacts and effects of medication use during air transport. Through a literature review and documentary research methodology, relevant facts about the precautions that should be taken regarding the use of medication in flights were considered. As a practical contribution, some important medications and their possible effects during flights are presented, as well as some warnings about medication interactions, and some advice for better quality air travel for the health of passengers and crew are given. As a theoretical contribution, this study gathers the scattered information presented in the literature about the problems that the use of medications during a flight can cause to the human body and possible recommendations. As social contribution, this study warns about the risks of self-medication, and establishes a basis for future discussions with society about the use of medication in flights.


2022 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Matthew E. Hirschtritt ◽  
Lyndsay A. Avalos ◽  
Varada Sarovar ◽  
Kathryn K. Ridout ◽  
Nancy C. Goler ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document